In plain terms

The claim being assessed: Pasteurized Akkermansia muciniphila MucT supplementation causes clinically meaningful metabolic improvement under the registered glycemic/function criteria in overweight insulin-resistant adults.

Where the evidence stands: Γ — Plausible mechanism. There is a believable biological story and partial support, but the causal step has not been demonstrated.

What this mechanism does: This makes the process worse or keeps it going, but something else starts it.

Strongest evidence for it: The original preregistered primary SC2 returns Γ, with Moderate appraisal confidence, because target/insulin-sensitivity effects do not establish the registered clinical glycemia/function benefit. The positive 2026 randomized weight-maintenance finding is separately scored Δ in supplemental SC5. No positive trial is discarded, and no generic class or all-metabolic-benefits negative conclusion is inferred.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Alternative ranked ahead

What this review means

Pasteurized MucT reduced weight regain in a 2026 trial; broader clinical glycemic benefits and interchangeability with other products remain unestablished.

Implications for health and treatment: The original preregistered primary SC2 returns Γ, with Moderate appraisal confidence, because target/insulin-sensitivity effects do not establish the registered clinical glycemia/function benefit. The positive 2026 randomized weight-maintenance finding is separately scored Δ in supplemental SC5. No positive trial is discarded, and no generic class or all-metabolic-benefits negative conclusion is inferred.

Limits for individual care: 59 primary reports with 2 selected partial-body examinations; evidence density, heterogeneous controls and reproducibility set the confidence, not correctness or access depth. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 59 primary reports; claims: 65; verified: 65; unverified: 0. Verification is bounded attribution. Access: 2 partial-body and 57 bounded abstract/status examinations. Literature cutoff: 2026-10-13; source examination UTC date: 2026-10-13. No complete-paper audit or blinded calibration claimed.

Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14 (4 corrections applied, A1–A4) and again on 2026-11-02 (7 corrections applied, A5–A11; see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

Pasteurized MucT reduced weight regain in a 2026 trial; broader clinical glycemic benefits and interchangeability with other products remain unestablished.

Deciding experiment: A blinded randomized exact-preparation MucT trial enrolls baseline-defined overweight insulin-resistant adults, prespecifies clinically meaningful HbA1c/glucose/function outcomes at 24 weeks, and stratifies low Akkermansia before outcomes with a registered interaction test. Retain full-population estimands and multiplicity controls. A separate replicated 24-week maintenance trial assesses objective regain after a pre-maintenance diet lead-in, with independent outcome/diet/activity measurement and a prespecified durability extension.

Belief versus evidence: The original preregistered primary SC2 returns Γ, with Moderate appraisal confidence, because target/insulin-sensitivity effects do not establish the registered clinical glycemia/function benefit. The positive 2026 randomized weight-maintenance finding is separately scored Δ in supplemental SC5. No positive trial is discarded, and no generic class or all-metabolic-benefits negative conclusion is inferred.

Best-supported rival: Specific host signaling with incomplete clinical translation (tournament rank 1). The nominal model, product-specific clinical glycemic benefit, ranks second. The 2019 original PMID31263284 directly separates insulin/HOMA marker changes from unchanged fasting glycemia/HbA1c. The new product-specific weight-maintenance trial PMID42120725 provides a separate true clinical positive; it prevents interpreting incomplete glycemic translation as absence of all product benefit. Tournament ranks measure fit to the registered claim, not each model's own HSEF level.

COMPETING MECHANISTIC MODELS

Rank 1: Specific host signaling with incomplete clinical translation (Γ). Microbial cell factors change barrier, insulin and lipid signaling without establishing every downstream clinical phenotype. Amuc_1100/P9 and other factor experiments plus the human marker-versus-glycemia dissociation fit this bounded mechanism. Necessary human factor mediation is unresolved; the positive weight-regain trial shows some clinical translation is possible.

Rank 2: Product-specific clinical glycemic benefit (Γ). Pasteurized MucT improves clinically meaningful glycemic/function outcomes in the registered population. Controlled target-marker effects and strain/factor experiments provide partial support. Clinical glycemia is null in the pilot body; the larger trial has a null insulin-sensitivity primary and exploratory subgroup signals.

Rank 3: Diet and baseline host/community state drive response (Δ). Dietary intervention and baseline ecology change glycemic/weight outcomes and microbial abundance together. High-fiber/energy-restriction and Mediterranean interventions change clinical glycemia; baseline abundance associates with dietary response. Diet does not explain away matched randomized product effects; taxon correlations do not isolate the dietary mediator.

Rank 4: Strain and processing alter functional factors (Γ). Different strains and preparation preserve or remove different active cell/factor functions. The one heat-killed preparation tested in 2013 failed, while later heat-killed (beagle [7], STZ mouse [44]) and pasteurized preparations improved selected measures; novel-species live preference and direct yogurt contrasts map functional differences. Animal processing differences are not universal human interchangeability rules and complete factor identity remains unresolved.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations. Ranks measure how well each model accounts for the evidence bearing on the registered claim, not each model's own HSEF level; rank 3 carries Δ for its own dietary scope while ranking below two Γ models on the registered claim.

FULL REVIEW

Registered claim and scope

Pasteurized Akkermansia muciniphila MucT supplementation improves clinically meaningful metabolic health in overweight insulin-resistant adults.

Evaluated wording: Pasteurized Akkermansia muciniphila MucT supplementation causes clinically meaningful metabolic improvement under the registered glycemic/function criteria in overweight insulin-resistant adults. The original broad metabolic-health wording is evaluated using its preregistered SC2 clinical glycemia/function gate, which excludes insulin-sensitivity markers alone. A newly discovered positive weight-maintenance proposition is scored separately as supplemental SC5, explicitly added after discovery and not the preregistered primary. This clarification does not turn a glycemic evidence gap into a claim that all metabolic benefits are absent.

The precise lead clinical proposition is SC2. Mechanism, competing-cause, generalization and safety companions remain separately reported; they do not replace the primary clinical endpoint.

Selection: position 13 in the registered editorial traffic-priority list; registration timestamp 2026-10-13T16:06:25.313824+00:00. Ranked editorial traffic priority rather than measured global popularity or a preset verdict. Registered claim assessed against original sources; no independent blinded calibration is claimed.

Evidence and causal interpretation

Rubric fit: Rubric 04 fits microbial and factor hypotheses, with rubric 06 governing the clinical metabolic proxy-versus-phenotype boundary. A randomized specified-product intervention changing an objective clinical phenotype is a human sufficiency perturbation; it need not prove the organism is an endogenous disease cause. Pasteurized nonliving cells are not a colonization or endogenous propagation experiment. Literal transfer/rescue requirements are quoted with the explicit product-intervention adaptation; forced recipient transfer remains bounded to its actual experimental system. Lifespan is not imposed on the non-lifespan treatment claim.

The human evidence contains both positives and boundaries. The 2019 exploratory MucT trial improves selected insulin/HOMA and cholesterol measures but its selected original Results say fasting glycemia and HbA1c do not change. Pasteurized participants start with worse insulin/sensitivity values, and analysis follows 32 completers from 40 enrolled. This is a useful physiological signal rather than a demonstrated clinically meaningful glycemic/function result.

The larger 2026 multicenter trial reports a null full-population primary Matsuda outcome. Its subsequent analyses find selected benefits among participants with low baseline Akkermansia and other strata. Low baseline is measurable before outcome, but that does not turn an exploratory analysis into a prespecified confirmed treatment subgroup. The live WST01 trial likewise has no whole-group HbA1c/weight advantage despite low-baseline colonization and benefit signals. Different live and pasteurized exposures remain separate.

The 2026 weight-maintenance trial is a true positive. Participants undergo a diet lead-in before randomized maintenance, and MucT produces less regain than placebo over 24 weeks. Because our registered primary specifies clinical glycemia/function in insulin-resistant adults, this newly encountered outcome is documented as supplemental SC5, added after discovery and nongating. The lead-in response precedes the assessed regain outcome, so this clinical context is an antecedent rather than a post-regain exclusion.

Strain and preparation matter. Early live-versus-heat-killed mouse findings differ from later pasteurized MucT or purified Amuc_1100 effects. Another Akkermansia species favors its live form. HB05 gives a real older-adult torque signal but selected body Results show no grip-strength change; it is another strain and population. WBF-011 has product-specific postprandial/A1c signals as a multi-strain/inulin mixture, while postbiotic yogurt has short-term selected anthropometric/liver results. None establishes that any retail product with the same genus name is interchangeable.

Fiber and microbial abundance are also distinct. Diet can improve glycemia and shift Akkermansia along with many taxa; inulin changes selected weight/insulin-need measures without changing its abundance or HbA1c. A healthier baseline abundance predicts some diet responses but can decline as metabolic measures improve. Transfers and factor manipulations establish the phenotype in their experimental recipients, not an endogenous human disease requirement. The review therefore keeps dietary and product successes while rejecting generic abundance-to-product inference.

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Subclaim matrix and aggregation

Preregistered aggregation: primary-subclaim. The original preregistered primary SC2 returns Γ, with Moderate appraisal confidence, because target/insulin-sensitivity effects do not establish the registered clinical glycemia/function benefit. The positive 2026 randomized weight-maintenance finding is separately scored Δ in supplemental SC5. No positive trial is discarded, and no generic class or all-metabolic-benefits negative conclusion is inferred. Sensitivities: weakest-link Α; primary-subclaim Γ; scope-matched Γ.

Supplemental SC5 was added after source discovery at 2026-10-13T16:18:20.009325+00:00; it was not preregistered and does not gate the original primary aggregation. The newly examined 2026 original PMID42120725 demonstrates weight-maintenance benefit. Preserve that genuine positive finding as a separately scored non-gating claim rather than expanding the preregistered glycemic/function primary endpoint retrospectively.

Decisive-perturbation inventory and causal tally

[1] The 40-enrolled/32-completed pilot found pasteurized Akkermansia improved insulin-sensitivity, insulin and cholesterol measures over three months; weight and fat differences were nonsignificant. Small exploratory biomarker effects do not establish clinical glycemic control/function; live/pasteurized arms and parent-trial secondary reports require shared-study grouping.

[2] Ninety randomized adults undergoing an eight-week diet followed by 24-week maintenance regained less weight with pasteurized MucT than placebo, 1.2 versus 3.2 kg. Genuine weight-maintenance benefit is not erased; baseline insulin-resistance eligibility and registered clinical glycemia/function endpoint require separate scope assessment, and active components were not isolated.

[3] A 100-person 12-week older-adult HB05 trial reported improved left-leg extensor torque and follistatin compared with placebo. Different strain and older functional population cannot establish MucT metabolic efficacy or all-strain generalization; a measured growth mediator is not necessity.

[4] A 142-person four-month MucT multicenter trial had a null primary Matsuda endpoint; subsequent exploratory baseline-low Akkermansia analyses found selected marker benefits. Do not replace full-population null with an unconfirmed subgroup; GLP1/insulin-sensitivity proxies and weight P=.06 do not establish registered clinical glycemia/function benefit.

[6] Pasteurized bacteria and purified Amuc_1100 improved metabolic/barrier measures in obese/diabetic mice; the protein interacts with TLR2 and partially reproduces effects. Mouse administration and a purified factor establish experimental sufficiency, not endogenous human necessity or clinically meaningful human outcomes.

[39] Live Akkermansia reversed HFD metabolic abnormalities in mice, whereas the tested heat-killed preparation did not; prebiotic normalization correlated with improved measures. Heat-killed and later pasteurized preparation protocols are not identical; experimental sufficiency does not prove endogenous human necessity or universal live superiority.

[40] Twelve-week live AKK-WST01 trial in 58 overweight/obese T2D adults had no whole-group HbA1c or weight advantage; low-baseline exploratory participants showed selected benefit and colonization. Different live strain and subgroup contrasts cannot establish broad pasteurized MucT efficacy; within-subgroup significance is not automatically an interaction or independent replicated subgroup.

[43] Twelve-week WBF-011 mixture trial in 76 T2D adults improved postprandial glucose primary outcome and reported lower HbA1c relative to placebo. The five-strain/inulin product is genuinely trialed but cannot identify Akkermansia component necessity or validate MucT, another formula or every probiotic.

Tally: 1 positive qualifying study unit across scoped subclaims; 42 screened discriminating contrast units. These are not independent causal lines or proof of full-claim necessity/sufficiency. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. The primary clinical glycemia/function positive tally is zero; supplemental weight-maintenance is one product-specific positive trial unit. Different products/strains and diet interventions cannot be counted as direct MucT clinical replication. Biomarkers, associations, purified factors and recipient transfers retain their exact system and outcome scope.

Cap audit, precedence and Β/Γ/Δ boundary

Recipient animal transfers and strain/factor addition may cross Δ for their actual phenotype and system. Universal cap 5 constrains inference to endogenous human propagation/causation, not a randomized pasteurized-product sufficiency trial. Biomarker cap 4 constrains marker-to-clinical inference for SC1/SC2; it does not cap a positive objective weight-regain intervention in SC5. No weakest-class cap is applied over a complementary same-scope convergent set.

Universal six-cap audit: All six universal caps were considered: cell-only inference, unperturbed association, ectopic expression, biomarker-only intervention, forced transfer/seeding, and inherited-to-sporadic scope transfer. Each binds its offered inference; complementary same-scope causal classes are assessed together rather than re-capped in isolation.

Gamma hard-rule audit: All microbiome and metabolism hard rules were considered. Recipient transfer, strain addition and factor rescue establish their experimental systems, not endogenous human necessity. Target engagement alone remains proxy-level; clinical glycemia/function and objective weight regain are assessed separately. No biomarker cap is used to erase the genuine positive randomized regain phenotype.

SC1 cap: “Biomarker change without functional/phenotypic change caps at Γ.” The specified preparation changes selected insulin, lipid and barrier-associated measures in the small 2019 trial, supported by experimental factor/barrier work. The 142-person trial has a null full-population primary Matsuda endpoint with exploratory subgroup marker changes. These observations show target-related physiological action, not a necessary isolated mediator or clinical phenotype crossing; the biomarker inference retains Γ.

SC2 cap: “Biomarker change without functional/phenotypic change caps at Γ.” The examined 2019 original body explicitly reports unchanged fasting glycemia and HbA1c, alongside improved HOMA/insulin markers. The larger MucT trial reports a null primary insulin-sensitivity endpoint and exploratory marker changes, not a verified full-scope clinically meaningful glycemic/function result. Other live strains, HB05 function and WBF mixtures cannot replace the registered product/population. Genuine 2026 MucT weight-maintenance benefit is separately retained in supplemental SC5.

SC3 cap: “Association plus mechanistic in vitro support, or host-pathway plausibility, caps at Γ.” Animal comparisons establish real strain/preparation effects, but directions differ: the one heat-killed preparation tested in 2013 failed, while later non-viable preparations improved selected measures (heat-killed EB-AMDK19 in beagles [7], heat-killed cells in STZ mice [44], and pasteurized preparations), and another species favors live treatment. The live AKK-WST01 human trial has no whole-group HbA1c/weight advantage, with low-baseline exploratory benefit. The HB05 older-adult functional and yogurt studies are genuine different-context results. These do not establish unrestricted clinical transfer across strains, preparations and baseline diseases.

SC1 field-valid definition: “ - Gnotobiotic or transfer experiment showing phenotype movement, at minimum - Even without defined-consortium precision or robust rescue, a transfer paradigm in vivo is the minimum that crosses this threshold

Per Cap precedence above, a gnotobiotic or forced-transfer experiment crosses Δ for the recipient-animal subclaim it was actually run in, while universal cap 5 (seeding or forced-transfer paradigms cap at Γ) still blocks the inference from that result to endogenous human biology — score the two scopes separately rather than choosing between the rules.” Positive full-scope result: no. The specified preparation changes selected insulin, lipid and barrier-associated measures in the small 2019 trial, supported by experimental factor/barrier work. The 142-person trial has a null full-population primary Matsuda endpoint with exploratory subgroup marker changes. These observations show target-related physiological action, not a necessary isolated mediator or clinical phenotype crossing; the biomarker inference retains Γ.

SC2 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. The examined 2019 original body explicitly reports unchanged fasting glycemia and HbA1c, alongside improved HOMA/insulin markers. The larger MucT trial reports a null primary insulin-sensitivity endpoint and exploratory marker changes, not a verified full-scope clinically meaningful glycemic/function result. Other live strains, HB05 function and WBF mixtures cannot replace the registered product/population. Genuine 2026 MucT weight-maintenance benefit is separately retained in supplemental SC5.

SC3 field-valid definition: “ - Gnotobiotic or transfer experiment showing phenotype movement, at minimum - Even without defined-consortium precision or robust rescue, a transfer paradigm in vivo is the minimum that crosses this threshold

Per Cap precedence above, a gnotobiotic or forced-transfer experiment crosses Δ for the recipient-animal subclaim it was actually run in, while universal cap 5 (seeding or forced-transfer paradigms cap at Γ) still blocks the inference from that result to endogenous human biology — score the two scopes separately rather than choosing between the rules.” Positive full-scope result: no. Animal comparisons establish real strain/preparation effects, but directions differ: the one heat-killed preparation tested in 2013 failed, while later non-viable preparations improved selected measures (heat-killed EB-AMDK19 in beagles [7], heat-killed cells in STZ mice [44], and pasteurized preparations), and another species favors live treatment. The live AKK-WST01 human trial has no whole-group HbA1c/weight advantage, with low-baseline exploratory benefit. The HB05 older-adult functional and yogurt studies are genuine different-context results. These do not establish unrestricted clinical transfer across strains, preparations and baseline diseases.

SC4 field-valid definition: “ - Gnotobiotic or transfer experiment showing phenotype movement, at minimum - Even without defined-consortium precision or robust rescue, a transfer paradigm in vivo is the minimum that crosses this threshold

Per Cap precedence above, a gnotobiotic or forced-transfer experiment crosses Δ for the recipient-animal subclaim it was actually run in, while universal cap 5 (seeding or forced-transfer paradigms cap at Γ) still blocks the inference from that result to endogenous human biology — score the two scopes separately rather than choosing between the rules.” Positive full-scope result: no. Endogenous abundance correlations or an unrelated probiotic effect cannot establish efficacy of an identified commercial formulation. Some directly tested products, including WBF-011, have genuine specific clinical signals, but that is product-specific evidence rather than the proposed generic-to-named inference. This unsupported broad inference is speculative and does not mean every named product is ineffective.

SC5 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: yes. The newly examined 90-person randomized trial reports lower 24-week regain with pasteurized MucT than placebo after a diet lead-in. This positive objective clinical phenotype crosses the first human sufficiency threshold for its prespecified maintenance setting. It was not our preregistered primary, does not establish glycemic efficacy in all insulin-resistant adults, and has not yet established generalization or independently replicated maintenance efficacy.

SC1 applied rubric adaptation (distinct from the unchanged literal criterion): Controlled product/host readouts establish physiological action, but insulin indices, lipids, GLP1 and LPS are not clinical glycemic/function outcomes or mediator necessity.

SC2 applied rubric adaptation (distinct from the unchanged literal criterion): Assess the registered strain/preparation, overweight insulin-resistant population, at least 12-week duration and clinical glycemic/function endpoint; do not substitute another strain or the separately added weight-regain outcome.

SC3 applied rubric adaptation (distinct from the unchanged literal criterion): Require direct strain/preparation clinical comparisons and baseline-defined generalization. Mouse transfer/addition crosses only its experimental context and does not establish endogenous human necessity.

SC4 applied rubric adaptation (distinct from the unchanged literal criterion): Require identifiable product-specific original trials, not a taxon signature or another formula; genuine trialed-product positives remain separate from generic inference.

SC5 applied rubric adaptation (distinct from the unchanged literal criterion): A matched randomized 24-week product/placebo contrast on objective regain after a pre-maintenance lead-in is a clinical sufficiency perturbation. This supplemental claim is openly post-discovery and does not gate or retrospectively redefine SC2.

SC1 literal Γ hard rule: “Association plus cell-culture metabolite assays” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Association plus in vitro immune readouts” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Any framework that has not crossed the transfer/rescue threshold in vivo” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Association plus cell-culture metabolite assays” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Association plus in vitro immune readouts” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Any framework that has not crossed the transfer/rescue threshold in vivo” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Association plus cell-culture metabolite assays” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Association plus in vitro immune readouts” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Any framework that has not crossed the transfer/rescue threshold in vivo” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

Upward threshold ladder

SC1 Δ: “Requires a transfer paradigm or causal perturbation in vivo.” Satisfied: no. Isolate the relevant product factor and host pathway at measured human exposure with functional phenotype and mechanism-specific controls.

SC2 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Replicate the exact product in baseline-defined overweight insulin-resistant adults with prospectively meaningful HbA1c/glucose/function endpoints over at least 12 weeks and full-population estimands.

SC3 Δ: “Requires a transfer paradigm or causal perturbation in vivo.” Satisfied: no. Directly compare strain/preparation and enroll prespecified disease/baseline strata; reproduce clinical benefit rather than only abundance or marker movement.

SC4 Δ: “Requires a transfer paradigm or causal perturbation in vivo.” Satisfied: no. Test each defined named formulation against matched placebo; mixtures need component subtraction/rescue before claiming Akkermansia necessity.

SC5 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: yes. The 90-person randomized maintenance trial (PMID42120725) reports 1.2 versus 3.2 kg regain over 24 weeks after an eight-week diet lead-in; the crossing is scoped to that maintenance setting and is unreplicated.

SC5 Ε: “Requires causal effect in constrained contexts, backgrounds, or species.” Satisfied: no. Replicate objective maintenance benefit across prespecified baseline clinical contexts and independently assess dietary intake/activity and durability; map boundaries without reclassifying regain failures.

Upper ladder: Exact strain/factor intervention and controlled clinical products make higher rungs reachable. However, the human primary clinical glycemic result, prospective subgroup replication and isolated necessary mediator are missing. A single positive maintenance trial crosses Δ in its supplemental scope but not independent convergence. Abundance and murine transfer cannot supply these human gates.

Independence: No final claim reaches Ζ. The 2019 pilot and endocannabinoid secondary share a study; experimental host factors, direct products and diet studies differ in scope and cannot be assembled as independent clinical glycemic MucT proof. A single systematic product/exposure or trial-context error could affect its limited clinical evidence.

Falsification and pitfalls

Clinical glycemia does not follow every target-marker improvement. 2019 fasting glycemia/HbA1c unchanged despite marker improvements; newer broad trial primary null. This caps the inference without erasing weight-maintenance benefit. Additional downgrade: False.

Microbiota association does not invariably transfer phenotype. Prediabetes donor transfer was null and another correlated taxon had no mouse supplement efficacy. Additional downgrade: False.

Confirmation by biomarker. HOMA, Matsuda, GLP1 and LPS cannot substitute for registered clinical glycemia/function.

Abundance treated as causality. Diet-linked abundance and baseline ecology do not validate a named formula.

Selective generalization. MucT, WST01, HB05, mixtures and yogurt differ in strain, process and eligibility.

Therapeutic effect misread as mechanistic proof. A true product phenotype does not establish factor or taxon necessity.

Scope fitted to outcome. Exploratory low-baseline effects remain exploratory; supplemental regain claim is openly post-discovery and nongating.

Replication confused with independence. The 2019 parent and secondary reports share participants; model-factor successes do not independently establish the human clinical gate.

Adversarial steelman: above, then below

Δ for the original primary could be defended by treating insulin-sensitivity improvement as clinically meaningful metabolism or borrowing the positive weight-regain trial. The strongest version would require an actual positive outcome under the preregistered clinical glycemic/function gate; that gate cannot be changed after discovery.

Β could be defended from taxon/health correlations alone, but it would ignore direct product interventions and factor experiments establishing partial-system action. The genuine supplemental weight-maintenance trial independently deserves Δ and must not be flattened into a generic low verdict.

Retain Γ for the original clinical glycemia/function primary because markers and different-product outcomes do not cross its fixed gate. Reject a correlation-only Β because controlled product/factor action supplies partial-system evidence. Separately retain Δ for supplemental objective regain benefit rather than using that new endpoint to change preregistered aggregation.

Final score, causal direction and M/S/D

The original preregistered primary SC2 returns Γ, with Moderate appraisal confidence, because target/insulin-sensitivity effects do not establish the registered clinical glycemia/function benefit. The positive 2026 randomized weight-maintenance finding is separately scored Δ in supplemental SC5. No positive trial is discarded, and no generic class or all-metabolic-benefits negative conclusion is inferred.

Administered preparation precedes measured host responses and the separately established maintenance effect; it is not produced by weight regain. Necessity/rate limitation and initiation/removal requirements for a primary driver are unproven. Other interventions alter metabolic trajectories. The coarse step 5 label describes contribution to maintenance/modification of an upstream metabolic state, not endogenous disease primacy.

Momentum: Mechanistic only. Completed MucT trials expand marker and weight-maintenance evidence, while Amuc_1100/P9 and other factor experiments narrow host pathways. No verified named pending trial addressing the registered clinical glycemia/function threshold was identified in this bounded search.

Stability: Stable. No verified named pending clinical glycemic/function result was identified; future prespecified low-baseline replication could change the claim, but a generic proposed study is not a named pending trigger.

Divergence: Contested. No invented field consensus or numeric belief gap is inferred from provider output or generic supplement promotion. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

A blinded randomized exact-preparation MucT trial enrolls baseline-defined overweight insulin-resistant adults, prespecifies clinically meaningful HbA1c/glucose/function outcomes at 24 weeks, and stratifies low Akkermansia before outcomes with a registered interaction test. Retain full-population estimands and multiplicity controls. A separate replicated 24-week maintenance trial assesses objective regain after a pre-maintenance diet lead-in, with independent outcome/diet/activity measurement and a prespecified durability extension.

Readout: Clinical glycemic control/function and adverse events for the original primary; objective regain for supplemental SC5; insulin/GLP1/barrier markers are secondary mechanistic leads. Controls: Matched product identity, process, dose, placebo, medications and diet/activity; prospective interaction and full-population analyses, not selection of outcome-defined responders; component controls for mechanism claims. Supporting: A clinically meaningful exact-product randomized glycemic/function result crosses the original first threshold; replicated maintenance benefit maps SC5 context and improves its generalization evidence. Falsifying: Marker movement without clinical benefit leaves SC2 uncrossed; a maintenance replication null maps a boundary without negating other verified context-specific results.

KNOWLEDGE GAPS

Prospectively meaningful clinical glycemic/function efficacy of exact pasteurized MucT over at least 12 weeks.

Independent maintenance replication and longer durability after a clearly defined pre-maintenance diet lead-in.

Prespecified baseline-low interactions with multiplicity control rather than within-subgroup significance comparisons.

Direct strain/preparation and commercial-product identity comparisons; named mixture success is not component necessity.

Necessary human factor/barrier mediator testing, distinct from purified factor sufficiency in mice.

Complete body/supplement review and long-term safety beyond small short trial populations.

REVIEWER NOTES

59 original reports were actually examined via primary abstracts/status metadata. Selected Methods/Results from two papers were examined at draft creation; additional complete-body access was unavailable through the attempted route and is not claimed. Most complete papers/supplements were not audited. Conceptual PMID41503894 was excluded despite a Journal Article index. PMID23899653 carries an expression of concern and is not decisive support. Supplemental SC5 was added after source discovery with an actual timestamp and explicit nongating status. These are original product, mechanism, comparator, diet and abundance reports, not 59 human MucT clinical trials. Observed signed-in Consensus Pro browser synthesis was reconciled in eight original-source comparisons; missing physical-function endpoints were not treated as measured nulls, review-mediated mixture statements were checked against the original trial, and the positive weight-maintenance result was preserved; no independent blinded review is claimed.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

Consensus and original-source reconciliation

Consensus reports improved insulin/HOMA with unchanged fasting glycemia/HbA1c. Selected original Methods and Results independently confirm HOMA calculation, unchanged fasting glycemia and HbA1c, and a not-markedly-hyperglycemic baseline. These clinical nulls do not erase the genuine marker effects or demonstrate ineffectiveness in every population. Original PMID31263284.

Consensus identifies 40 enrolled and 32 completers. The original body confirms 11 placebo, 12 pasteurized and nine live completers after personal, antibiotic-use and protocol exclusions, with higher insulin/lower sensitivity in the pasteurized group at baseline. This imbalance and completion analysis limit a definitive clinical interpretation; the provider summary does not replace those Methods details. Original PMID31263284.

Consensus describes the 142-person trial primary Matsuda null with subsequent low-baseline marker signals. The examined original abstract confirms the intention-to-treat primary null and labels subsequent analyses exploratory, including weight P=.06 in low-baseline participants. We did not obtain its complete Methods/Results through the attempted public route, so detailed recruitment disruptions and full analysis-plan claims in the provider are not treated as independently verified body findings. Original PMID42343233.

Consensus correctly preserves lower 24-week regain after an eight-week diet lead-in. The original abstract confirms 90 participants, the maintenance outcome and lower regain with MucT than placebo. This is openly scored as supplemental SC5 added after discovery; the primary glycemic/function gate remains unchanged. Pre-maintenance lead-in eligibility precedes assessed regain and does not exclude later regain failures retrospectively. Original PMID42120725.

The provider says direct human trials show no measurable physical-function gains while citing MucT metabolic/maintenance studies and does not use HB05 as a named supporting anchor. A missing endpoint is not a tested null. Our selected HB05 original Methods/Results show a different strain in older adults, positive left/combined extensor torque, unchanged grip and myostatin, and per-protocol analysis. Those positives remain real but cannot be extrapolated to MucT clinical metabolism. Original PMID39683431.

Consensus supports its multi-strain glucose/HbA1c statement through review/mechanism citations. Our examined WBF-011 original instead supplies the direct 76-person 12-week trial: the five-strain/inulin mixture improves postprandial glucose and reports a HbA1c signal. This specific product evidence cannot isolate Akkermansia component necessity or validate other commercial formulas. Reviews do not add primary-count credit. Original PMID32675291.

Consensus separates live WST01 from pasteurized MucT. The original 58-person 12-week trial abstract confirms no overall HbA1c/weight advantage and low-baseline colonization/clinical signals. Baseline abundance is measurable before outcomes, but exploratory subgroup and within-group significance cannot automatically establish a prospective replicated treatment interaction. Original PMID39879980.

Consensus reports selected postbiotic-yogurt anthropometric benefits and says physical fitness was not altered. The original abstract reports waist, fat, AST and appetite comparisons over eight weeks, without a documented physical-fitness contrast. We preserve its product-specific positive endpoints and treat physical function as not established from the examined record, rather than infer a measured null. Original PMID40451504.

Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.

Research timeline and gaps: Pasteurized Akkermansia and Metabolic Health

Selected publication milestones, not an exhaustive history or discovery priority claim.

2013 — Early mouse experiments distinguish viable bacteria from the tested heat-killed preparation. Original PMID23671105.

2016 — Human diet intervention links baseline microbial ecology with response without randomizing bacterial abundance. Original PMID26100928.

2017 — Pasteurized cells and Amuc_1100 provide experimental metabolic/barrier sufficiency in mice. Original PMID27892954.

2018 — Prediabetes taxon association does not transfer impaired glucose regulation to recipient mice. Original PMID29379988.

2018 — Akkermansia vesicles provide experimental barrier and glucose effects in recipient models. Original PMID29472701.

2019 — The first human pilot shows insulin/HOMA and cholesterol signals but unchanged clinical glycemia in selected body Results. Original PMID31263284.

2020 — A defined multi-strain/inulin formulation has a genuine product-specific glucose-control signal. Original PMID32675291.

2021 — A shared pilot-trial secondary analysis narrows a proposed lipid mediator without proving necessity. Original PMID33477821.

2021 — P9 factor and host-pathway experiments narrow a distinct experimental mechanism. Original PMID33820962.

2021 — Direct mouse live/pasteurized comparisons map strain/preparation effects. Original PMID34683361.

2022 — Another Akkermansia species favors its live form, challenging universal processing superiority. Original PMID35805168.

2024 — A different HB05 product improves selected older-adult torque outcomes while grip remains unchanged. Original PMID39683431.

2025 — Live WST01 human trial has a whole-group clinical null with exploratory low-baseline signals. Original PMID39879980.

2025 — A short postbiotic-yogurt trial provides formulation-specific selected anthropometric/liver effects. Original PMID40451504.

2026 — Product-specific randomized maintenance trial shows less regain; this positive becomes explicitly post-discovery supplemental SC5. Original PMID42120725.

2026 — Larger MucT trial has a null primary Matsuda endpoint and exploratory baseline-low marker signals. Original PMID42343233.

2026 — Inulin changes selected outcomes without raising Akkermansia or improving HbA1c/CGM. Original PMID41636295.

2026 — A high-fiber/energy-restriction intervention changes clinical glycemia and several taxa without isolating one microbial mediator. Original PMID42116498.

Research gaps

Prospectively meaningful clinical glycemic/function efficacy of exact pasteurized MucT over at least 12 weeks.

Independent maintenance replication and longer durability after a clearly defined pre-maintenance diet lead-in.

Prespecified baseline-low interactions with multiplicity control rather than within-subgroup significance comparisons.

Direct strain/preparation and commercial-product identity comparisons; named mixture success is not component necessity.

Necessary human factor/barrier mediator testing, distinct from purified factor sufficiency in mice.

Complete body/supplement review and long-term safety beyond small short trial populations.

Boundary experiment

A blinded randomized exact-preparation MucT trial enrolls baseline-defined overweight insulin-resistant adults, prespecifies clinically meaningful HbA1c/glucose/function outcomes at 24 weeks, and stratifies low Akkermansia before outcomes with a registered interaction test. Retain full-population estimands and multiplicity controls. A separate replicated 24-week maintenance trial assesses objective regain after a pre-maintenance diet lead-in, with independent outcome/diet/activity measurement and a prespecified durability extension.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14.

Scope of checks. All 59 REFERENCES PMIDs verified against PubMed get_article_metadata (59/59 resolve to the stated first author, journal and DOI; 0 failures). The excluded conceptual record PMID41503894 was also resolved. 13 load-bearing claims were spot-checked against the cited abstracts, concentrating on those that support the headline letter: the 2019 pilot enrolment/completion split and the unchanged fasting glycemia/HbA1c; the 2026 maintenance trial's n, lead-in design and 1.2 vs 3.2 kg regain contrast; the 142-person trial's null intention-to-treat Matsuda primary, its exploratory low-baseline analyses and the weight P=.06; the HB05 trial's n, duration, left-leg extensor torque and follistatin results; the AKK-WST01 trial's n, duration and absence of a whole-group HbA1c/weight advantage; the WBF-011 trial's n and glucose-AUC primary outcome; and the inulin pilot's unchanged Akkermansia abundance and HbA1c/CGM. Scoring logic was re-derived: hard caps precede aggregation, the declared primary-subclaim rule is applied as written to SC2, the Ε rung is not used to set the headline, and the Β/Γ/Δ boundary and Ζ independence basis were checked. Framework validator re-run.

Findings

Rejected findings (checked, no change). (i) Reference years printed as print/issue years that differ from the PubMed e-pub year — refs 6, 28, 33, 35, 37, 38, 42, 55. Print-versus-e-pub differences are a declared non-error; ref 35 (Frugé, print 2020, e-pub 2018) was checked against the journal citation and is correct as printed. (ii) PubMed title fields that drop italicised species or strain names (e.g. "PasteurizedHB05", "Muc") — a declared non-error of the PubMed title field, not of this review. (iii) Confidence band Moderate: the band itself is unchanged, but see finding A4 for the rationale rewrite. (iv) Secondary rubric 06 literal Δ criterion ("intervention producing reproducible lifespan/healthspan extension") quoted for SC2 and SC5, which are not lifespan claims: the review quotes the literal criterion and states a separate applied adaptation for each subclaim, and the body explicitly records that "Lifespan is not imposed on the non-lifespan treatment claim." Rewriting a quoted framework criterion would be a larger error than the awkwardness; recorded as a residual limitation instead. (v) Tally arithmetic: prose "1 positive qualifying study units … 42 screened discriminating contrast units" matches causal_tally_audit.tally_after_audit = 1 and screened_discriminating_contrasts = 42. The eight numbered inventory entries are the decisive-perturbation inventory, not the screened total; no mismatch. (vi) Momentum "Mechanistic only" is correct — no named pending trial is claimed. (vii) No collective-author rendering defect, no empty DOI field, no "PMIDnot supplied" string and no glued-numeral defect was found in this review. (viii) Levels: SC1–SC5 and the headline Γ follow from the quoted caps and the declared aggregation rule; no letter required a change.

Scorecard change. final_score.confidence_rationale only; hsef_level, confidence, subclaim levels and all other fields are unchanged. Validator re-run: PASS.

Residual limitations. Two of 59 records were examined at partial-body depth; the remainder are abstract/status examinations, as the banner states. The expression of concern the REVIEWER NOTES attribute to PMID23899653 could not be confirmed through the available PubMed metadata route (the tool does not expose comments-corrections links); the statement is a caution attached to a non-load-bearing reference and was left as written. Rubric 06's literal aging wording remains in the threshold-ladder quotations.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.

Second adversarial pass (2026-11-02)

Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-11-02. All 59 reference PMIDs re-verified against PubMed (59/59 resolve; the excluded conceptual record PMID41503894 also resolves); 15 load-bearing claims spot-checked, including the 2019 pilot against its PMC full text. Level Γ and confidence Moderate unchanged. The full log is ADVERSARIAL_REVIEW.akkermansia-metabolic-health.md.

Approval: Following the second adversarial pass and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-11-02.

REFERENCES

1. Depommier C, Everard A, Druart C et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature medicine. 2019. PMID 31263284. DOI: 10.1038/s41591-019-0495-2. Access: full_text_partial. Study: MUCT-NCT02637115.

2. Mount S, Canfora EE, Jocken JW et al. Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial. Nature medicine. 2026. PMID 42120725. DOI: 10.1038/s41591-026-04394-7. Access: abstract_metadata. Study: MUCT-NCT05417360.

3. Kang CH, Jung ES, Jung SJ et al. Pasteurized Akkermansia muciniphila HB05 (HB05P) Improves Muscle Strength and Function: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutrients. 2024. PMID 39683431. DOI: 10.3390/nu16234037. Access: full_text_partial. Study: PMID39683431.

4. Suenaert P, Segers A, Rymenans L et al. Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels. Gut microbes. 2026. PMID 42343233. DOI: 10.1080/19490976.2026.2690689. Access: abstract_metadata. Study: MUCT-NCT05114018.

5. Depommier C, Vitale RM, Iannotti FA et al. Beneficial Effects of Akkermansia muciniphila Are Not Associated with Major Changes in the Circulating Endocannabinoidome but Linked to Higher Mono-Palmitoyl-Glycerol Levels as New PPARα Agonists. Cells. 2021. PMID 33477821. DOI: 10.3390/cells10010185. Access: abstract_metadata. Study: MUCT-NCT02637115.

6. Plovier H, Everard A, Druart C et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nature medicine. 2017. PMID 27892954. DOI: 10.1038/nm.4236. Access: abstract_metadata. Study: PMID27892954.

7. Hong MG, Lee Y, Chung WS et al. Supplementation with heat-killed Akkermansia muciniphila EB-AMDK19 counteracts diet-induced overweight in beagles. Archives of animal nutrition. 2024. PMID 39264284. DOI: 10.1080/1745039X.2024.2397221. Access: abstract_metadata. Study: PMID39264284.

8. Feng S, Wang W, Zhang X et al. Investigating the role of Akkermansia muciniphila Akk11 in modulating obesity and intestinal dysbiosis: a comparative study of live and pasteurized treatments. Frontiers in microbiology. 2025. PMID 41277957. DOI: 10.3389/fmicb.2025.1638771. Access: abstract_metadata. Study: PMID41277957.

9. Choi Y, Bose S, Seo J et al. Effects of Live and Pasteurized Forms of Akkermansia from the Human Gut on Obesity and Metabolic Dysregulation. Microorganisms. 2021. PMID 34683361. DOI: 10.3390/microorganisms9102039. Access: abstract_metadata. Study: PMID34683361.

10. Ashrafian F, Keshavarz Azizi Raftar S, Lari A et al. Extracellular vesicles and pasteurized cells derived from Akkermansia muciniphila protect against high-fat induced obesity in mice. Microbial cell factories. 2021. PMID 34863163. DOI: 10.1186/s12934-021-01709-w. Access: abstract_metadata. Study: PMID34863163.

11. Kumar R, Kane H, Wang Q et al. Identification and Characterization of a Novel Species of Genus Akkermansia with Metabolic Health Effects in a Diet-Induced Obesity Mouse Model. Cells. 2022. PMID 35805168. DOI: 10.3390/cells11132084. Access: abstract_metadata. Study: PMID35805168.

12. Huang B, Xian Y, Xue W et al. Probiotic attributes and safety profile of AKM Lab-01: a novel Akkermansia muciniphila strain combating obesity and metabolic disorders in diet-induced obese mice. Frontiers in microbiology. 2025. PMID 41568048. DOI: 10.3389/fmicb.2025.1627870. Access: abstract_metadata. Study: PMID41568048.

13. Kaur I, Suri V, Sachdeva N et al. Efficacy of multi-strain probiotic along with dietary and lifestyle modifications on polycystic ovary syndrome: a randomised, double-blind placebo-controlled study. European journal of nutrition. 2022. PMID 35857132. DOI: 10.1007/s00394-022-02959-z. Access: abstract_metadata. Study: PMID35857132.

14. Sato J, Kanazawa A, Azuma K et al. Probiotic reduces bacterial translocation in type 2 diabetes mellitus: A randomised controlled study. Scientific reports. 2017. PMID 28935921. DOI: 10.1038/s41598-017-12535-9. Access: abstract_metadata. Study: PMID28935921.

15. Khiaolaongam W, Boonyapranai K, Sitdhipol J et al. Bifidobacterium animalis subsp. lactis TISTR 2591 Improves Glycemic Control and Immune Response in Adults with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Crossover Clinical Trial. Nutrients. 2025. PMID 41097174. DOI: 10.3390/nu17193097. Access: abstract_metadata. Study: PMID41097174.

16. Ratajczak M, Bilska A, Musialik K et al. Multi-strain probiotic reduces gastrointestinal side effects in women with elevated HOMA-IR index treated with metformin: a 12-week randomised controlled trial. Frontiers in endocrinology. 2026. PMID 41852479. DOI: 10.3389/fendo.2026.1765741. Access: abstract_metadata. Study: PMID41852479.

17. Culpepper T, Rowe CC, Rusch CT et al. Three probiotic strains exert different effects on plasma bile acid profiles in healthy obese adults: randomised, double-blind placebo-controlled crossover study. Beneficial microbes. 2019. PMID 31090458. DOI: 10.3920/BM2018.0151. Access: abstract_metadata. Study: PMID31090458.

18. Oh MR, Jang HY, Lee SY et al. Lactobacillus plantarum HAC01 Supplementation Improves Glycemic Control in Prediabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2021. PMID 34371847. DOI: 10.3390/nu13072337. Access: abstract_metadata. Study: PMID34371847.

19. Simon MC, Strassburger K, Nowotny B et al. Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept. Diabetes care. 2015. PMID 26084343. DOI: 10.2337/dc14-2690. Access: abstract_metadata. Study: PMID26084343.

20. Gøbel RJ, Larsen N, Jakobsen M et al. Probiotics to adolescents with obesity: effects on inflammation and metabolic syndrome. Journal of pediatric gastroenterology and nutrition. 2012. PMID 22695039. DOI: 10.1097/MPG.0b013e318263066c. Access: abstract_metadata. Study: PMID22695039.

21. Halkjær SI, de Knegt VE, Kallemose T et al. No effect of multi-strain probiotic supplementation on metabolic and inflammatory markers and newborn body composition in pregnant women with obesity: Results from a randomized, double-blind placebo-controlled study. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2023. PMID 37580231. DOI: 10.1016/j.numecd.2023.07.030. Access: abstract_metadata. Study: PMID37580231.

22. Hasain Z, Raja Ali RA, Ahmad HF et al. The Roles of Probiotics in the Gut Microbiota Composition and Metabolic Outcomes in Asymptomatic Post-Gestational Diabetes Women: A Randomized Controlled Trial. Nutrients. 2022. PMID 36145254. DOI: 10.3390/nu14183878. Access: abstract_metadata. Study: PMID36145254.

23. Dolatkhah N, Hajifaraji M, Abbasalizadeh F et al. Is there a value for probiotic supplements in gestational diabetes mellitus? A randomized clinical trial. Journal of health, population, and nutrition. 2015. PMID 26825666. DOI: 10.1186/s41043-015-0034-9. Access: abstract_metadata. Study: PMID26825666.

24. Okuka N, Milinkovic N, Velickovic K et al. Beneficial effects of a new probiotic formulation on adipocytokines, appetite-regulating hormones, and metabolic parameters in obese women. Food & function. 2024. PMID 38953736. DOI: 10.1039/d4fo01269k. Access: abstract_metadata. Study: PMID38953736.

25. Asemi Z, Zare Z, Shakeri H et al. Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Annals of nutrition & metabolism. 2013. PMID 23899653. DOI: 10.1159/000349922. Access: abstract_metadata. Study: PMID23899653. Editorial notice: expression of concern, PMID 37334997.

26. Solito A, Bozzi Cionci N, Calgaro M et al. Supplementation with Bifidobacterium breve BR03 and B632 strains improved insulin sensitivity in children and adolescents with obesity in a cross-over, randomized double-blind placebo-controlled trial. Clinical nutrition (Edinburgh, Scotland). 2021. PMID 34229263. DOI: 10.1016/j.clnu.2021.06.002. Access: abstract_metadata. Study: PMID34229263.

27. Xu D, Feng M, Chu Y et al. The Prebiotic Effects of Oats on Blood Lipids, Gut Microbiota, and Short-Chain Fatty Acids in Mildly Hypercholesterolemic Subjects Compared With Rice: A Randomized, Controlled Trial. Frontiers in immunology. 2021. PMID 34956218. DOI: 10.3389/fimmu.2021.787797. Access: abstract_metadata. Study: PMID34956218.

28. Hornero-Ramirez H, Morisette A, Marcotte B et al. Multifunctional dietary approach reduces intestinal inflammation in relation with changes in gut microbiota composition in subjects at cardiometabolic risk: the SINFONI project. Gut microbes. 2025. PMID 39710576. DOI: 10.1080/19490976.2024.2438823. Access: abstract_metadata. Study: PMID39710576.

29. Dong TS, Luu K, Lagishetty V et al. A High Protein Calorie Restriction Diet Alters the Gut Microbiome in Obesity. Nutrients. 2020. PMID 33096810. DOI: 10.3390/nu12103221. Access: abstract_metadata. Study: PMID33096810.

30. Wang L, Liang C, Yu J et al. Timing matters in type 2 diabetes: Early high-Fiber nutrition enhances glycemic control and reshapes gut microbiota. Food research international (Ottawa, Ont.). 2026. PMID 42116498. DOI: 10.1016/j.foodres.2026.119257. Access: abstract_metadata. Study: PMID42116498.

31. Wu CK, Cheng IS, Chung YC et al. The Effects of a Prebiotic Formula Promoting Akkermansia muciniphila (AKK) on Gut Health: A Single-Centre, Randomised Controlled Trial. International journal of medical sciences. 2026. PMID 42158814. DOI: 10.7150/ijms.125881. Access: abstract_metadata. Study: PMID42158814.

32. Bush JR, Baisley J, Harding SV et al. Consumption of Solnul™ Resistant Potato Starch Produces a Prebiotic Effect in a Randomized, Placebo-Controlled Clinical Trial. Nutrients. 2023. PMID 37049425. DOI: 10.3390/nu15071582. Access: abstract_metadata. Study: PMID37049425.

33. Igudesman D, Crandell JL, Corbin KD et al. Associations of Dietary Intake with the Intestinal Microbiota and Short-Chain Fatty Acids Among Young Adults with Type 1 Diabetes and Overweight or Obesity. The Journal of nutrition. 2023. PMID 36841667. DOI: 10.1016/j.tjnut.2022.12.017. Access: abstract_metadata. Study: PMID36841667.

34. Ojetti V, Saviano A, Rizzi A et al. Efficacy of inulin supplementation in metabolic control and Akkermansia muciniphila levels in subjects with type 1 diabetes: a pilot study. European review for medical and pharmacological sciences. 2026. PMID 41636295. DOI: 10.26355/eurrev_202601_37645. Access: abstract_metadata. Study: PMID41636295.

35. Frugé AD, Van der Pol W, Rogers LQ et al. Fecal Akkermansia muciniphila Is Associated with Body Composition and Microbiota Diversity in Overweight and Obese Women with Breast Cancer Participating in a Presurgical Weight Loss Trial. Journal of the Academy of Nutrition and Dietetics. 2020. PMID 30420171. DOI: 10.1016/j.jand.2018.08.164. Access: abstract_metadata. Study: NCT02224807.

36. Fan J, le Gall G, Malcomson FC et al. Distinct effects of supplementation with resistant starch and polydextrose on plasma and faecal bile acid profile and associations with gut microbiota: a randomised, controlled intervention in healthy participants. European journal of nutrition. 2026. PMID 42489745. DOI: 10.1007/s00394-026-04060-1. Access: abstract_metadata. Study: DISC-NCT01214681.

37. Vitale M, Giacco R, Laiola M et al. Acute and chronic improvement in postprandial glucose metabolism by a diet resembling the traditional Mediterranean dietary pattern: Can SCFAs play a role? Clinical nutrition (Edinburgh, Scotland). 2021. PMID 32698959. DOI: 10.1016/j.clnu.2020.05.025. Access: abstract_metadata. Study: PMID32698959.

38. Velikonja A, Lipoglavšek L, Zorec M et al. Alterations in gut microbiota composition and metabolic parameters after dietary intervention with barley beta glucans in patients with high risk for metabolic syndrome development. Anaerobe. 2019. PMID 30396006. DOI: 10.1016/j.anaerobe.2018.11.002. Access: abstract_metadata. Study: PMID30396006.

39. Everard A, Belzer C, Geurts L et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proceedings of the National Academy of Sciences of the United States of America. 2013. PMID 23671105. DOI: 10.1073/pnas.1219451110. Access: abstract_metadata. Study: PMID23671105.

40. Zhang Y, Liu R, Chen Y et al. Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut. Cell metabolism. 2025. PMID 39879980. DOI: 10.1016/j.cmet.2024.12.010. Access: abstract_metadata. Study: WST01-NCT04797442.

41. Yoon HS, Cho CH, Yun MS et al. Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice. Nature microbiology. 2021. PMID 33820962. DOI: 10.1038/s41564-021-00880-5. Access: abstract_metadata. Study: PMID33820962.

42. Dao MC, Everard A, Aron-Wisnewsky J et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. 2016. PMID 26100928. DOI: 10.1136/gutjnl-2014-308778. Access: abstract_metadata. Study: DAO-NCT01314690.

43. Perraudeau F, McMurdie P, Bullard J et al. Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation. BMJ open diabetes research & care. 2020. PMID 32675291. DOI: 10.1136/bmjdrc-2020-001319. Access: abstract_metadata. Study: WBF-NCT03893422.

44. Zhang C, Wang Z, Liu X et al. Akkermansia muciniphila administration ameliorates streptozotocin-induced hyperglycemia and muscle atrophy by promoting IGF2 secretion from mouse intestine. iMeta. 2024. PMID 39429872. DOI: 10.1002/imt2.237. Access: abstract_metadata. Study: PMID39429872.

45. Zhang F, Tian J, Li JT et al. Akkermansia muciniphila alleviates metabolic disorders through gut microbiota-mediated tryptophan regulation. AMB Express. 2025. PMID 41273480. DOI: 10.1186/s13568-025-01986-3. Access: abstract_metadata. Study: PMID41273480.

46. Li J, Ma Z, Zhang J et al. Akkermansia muciniphila-derived L-norleucine modulates FABP1-dependent fatty acid transport. Proceedings of the National Academy of Sciences of the United States of America. 2026. PMID 42207914. DOI: 10.1073/pnas.2533286123. Access: abstract_metadata. Study: PMID42207914.

47. Mihele AI, Lazar L. Akkermansia muciniphila in patients with metabolic dysfunction-associated steatotic liver disease. Journal of medicine and life. 2024. PMID 39628971. DOI: 10.25122/jml-2024-0342. Access: abstract_metadata. Study: PMID39628971.

48. Paone P, Petitfils C, Puel A et al. Akkermansia muciniphila modulates intestinal mucus composition to counteract high-fat diet-induced obesity in mice. Gut microbes. 2026. PMID 41511159. DOI: 10.1080/19490976.2025.2612580. Access: abstract_metadata. Study: PMID41511159.

49. Allin KH, Tremaroli V, Caesar R et al. Aberrant intestinal microbiota in individuals with prediabetes. Diabetologia. 2018. PMID 29379988. DOI: 10.1007/s00125-018-4550-1. Access: abstract_metadata. Study: PMID29379988.

50. Aalipanah E, Askarpour M, Eskandari MH et al. Comparing the effects of yogurt containing Akkermansia muciniphilia postbiotic with yogurt containing Lactobacillus rhamnosus postbiotic on body composition, biochemical indices, appetite, and depression scores in overweight or obese adults: A randomized, double-blind, controlled clinical trial. Clinical nutrition ESPEN. 2025. PMID 40451504. DOI: 10.1016/j.clnesp.2025.05.045. Access: abstract_metadata. Study: PMID40451504.

51. Sun L, Zhang Y, Dong W et al. Akkermansia muciniphila-derived hypoacylated rough-type lipopolysaccharides alleviate diet-induced obesity via activation of TLR4-IL-23-IL-22 immune axis. iMeta. 2025. PMID 41112049. DOI: 10.1002/imt2.70066. Access: abstract_metadata. Study: PMID41112049.

52. Qu D, Chen M, Zhu H et al. Akkermansia muciniphila and its outer membrane protein Amuc_1100 prevent high-fat diet-induced nonalcoholic fatty liver disease in mice. Biochemical and biophysical research communications. 2023. PMID 37866242. DOI: 10.1016/j.bbrc.2023.149131. Access: abstract_metadata. Study: PMID37866242.

53. Chelakkot C, Choi Y, Kim DK et al. Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. Experimental & molecular medicine. 2018. PMID 29472701. DOI: 10.1038/emm.2017.282. Access: abstract_metadata. Study: PMID29472701.

54. Rao Y, Kuang Z, Li C et al. Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis. Gut microbes. 2021. PMID 34030573. DOI: 10.1080/19490976.2021.1927633. Access: abstract_metadata. Study: PMID34030573.

55. Zhuge A, Li S, Han S et al. Akkermansia muciniphila-derived acetate activates the hepatic AMPK/SIRT1/PGC-1α axis to alleviate ferroptosis in metabolic-associated fatty liver disease. Acta pharmaceutica Sinica. B. 2025. PMID 40041901. DOI: 10.1016/j.apsb.2024.10.010. Access: abstract_metadata. Study: PMID40041901.

56. Van Hul M, Le Roy T, Prifti E et al. From correlation to causality: the case of Subdoligranulum. Gut microbes. 2020. PMID 33323004. DOI: 10.1080/19490976.2020.1849998. Access: abstract_metadata. Study: PMID33323004.

57. Hamade H, Stamps JT, Stamps DT et al. BATF3 Protects Against Metabolic Syndrome and Maintains Intestinal Epithelial Homeostasis. Frontiers in immunology. 2022. PMID 35812447. DOI: 10.3389/fimmu.2022.841065. Access: abstract_metadata. Study: PMID35812447.

58. Matsuzaki M, Imai A, Yanagisawa K et al. Mucin-dependent transcriptional dynamics of Akkermansia muciniphila in co-culture with human colonic organoids. Bioscience, biotechnology, and biochemistry. 2025. PMID 40795248. DOI: 10.1093/bbb/zbaf121. Access: abstract_metadata. Study: PMID40795248.

59. Elzinga J, Narimatsu Y, de Haan N et al. Binding of Akkermansia muciniphila to mucin is O-glycan specific. Nature communications. 2024. PMID 38811534. DOI: 10.1038/s41467-024-48770-8. Access: abstract_metadata. Study: PMID38811534.

Source-specific evidence cards

[1] Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study.

Shows: The 40-enrolled/32-completed pilot found pasteurized Akkermansia improved insulin-sensitivity, insulin and cholesterol measures over three months; weight and fat differences were nonsignificant.

Does not show: Small exploratory biomarker effects do not establish clinical glycemic control/function; live/pasteurized arms and parent-trial secondary reports require shared-study grouping.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:Online Methods:paragraph0, 0:Online Methods:paragraph1, 0:Online Methods:paragraph2, 0:Online Methods:paragraph3, 0:Online Methods:paragraph7, 0:Online Methods:paragraph8, 7:Main text (unsectioned body paragraphs):paragraph3, 7:Main text (unsectioned body paragraphs):paragraph4, 7:Main text (unsectioned body paragraphs):paragraph5, 7:Main text (unsectioned body paragraphs):paragraph9, 7:Main text (unsectioned body paragraphs):paragraph13, 7:Main text (unsectioned body paragraphs):paragraph14. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[2] Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial.

Shows: Ninety randomized adults undergoing an eight-week diet followed by 24-week maintenance regained less weight with pasteurized MucT than placebo, 1.2 versus 3.2 kg.

Does not show: Genuine weight-maintenance benefit is not erased; baseline insulin-resistance eligibility and registered clinical glycemia/function endpoint require separate scope assessment, and active components were not isolated.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3, SC5.

[3] Pasteurized Akkermansia muciniphila HB05 (HB05P) Improves Muscle Strength and Function: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Shows: A 100-person 12-week older-adult HB05 trial reported improved left-leg extensor torque and follistatin compared with placebo.

Does not show: Different strain and older functional population cannot establish MucT metabolic efficacy or all-strain generalization; a measured growth mediator is not necessity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:2. Materials and Methods:paragraph1, 1:2. Materials and Methods:paragraph2, 1:2. Materials and Methods:paragraph3, 1:2. Materials and Methods:paragraph5, 2:3. Results:paragraph0, 2:3. Results:paragraph2, 2:3. Results:paragraph3, 2:3. Results:paragraph4, 2:3. Results:paragraph5. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[4] Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels.

Shows: A 142-person four-month MucT multicenter trial had a null primary Matsuda endpoint; subsequent exploratory baseline-low Akkermansia analyses found selected marker benefits.

Does not show: Do not replace full-population null with an unconfirmed subgroup; GLP1/insulin-sensitivity proxies and weight P=.06 do not establish registered clinical glycemia/function benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[5] Beneficial Effects of Akkermansia muciniphila Are Not Associated with Major Changes in the Circulating Endocannabinoidome but Linked to Higher Mono-Palmitoyl-Glycerol Levels as New PPARα Agonists.

Shows: Secondary analysis of the pilot found no global endocannabinoidome change, with selected mono-palmitoylglycerol changes and PPARalpha activity support.

Does not show: Shares parent trial; univariate lipid differences and receptor activity do not isolate necessary human mediation or clinical benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[6] A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice.

Shows: Pasteurized bacteria and purified Amuc_1100 improved metabolic/barrier measures in obese/diabetic mice; the protein interacts with TLR2 and partially reproduces effects.

Does not show: Mouse administration and a purified factor establish experimental sufficiency, not endogenous human necessity or clinically meaningful human outcomes.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[7] Supplementation with heat-killed Akkermansia muciniphila EB-AMDK19 counteracts diet-induced overweight in beagles.

Shows: Heat-killed EB-AMDK19 reduced diet-induced weight/fat/triglyceride gain in beagles over 12 weeks.

Does not show: Different strain and canine prevention setting cannot establish human MucT clinical efficacy or universal pasteurized/live equivalence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[8] Investigating the role of Akkermansia muciniphila Akk11 in modulating obesity and intestinal dysbiosis: a comparative study of live and pasteurized treatments.

Shows: Live/pasteurized Akk11 improved adiposity and barrier measures in HFD mice with different microbial and fatty-acid responses.

Does not show: Single-strain mouse exposure and differing fermentation responses do not establish formulation interchangeability in human clinical disease.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[9] Effects of Live and Pasteurized Forms of Akkermansia from the Human Gut on Obesity and Metabolic Dysregulation.

Shows: Two strains in live/pasteurized form improved 12-week HFD mouse metabolic measures; pasteurized forms improved glucose tolerance more.

Does not show: Mouse formulation comparison maps context, not human universal equivalence; administered microbes do not prove endogenous necessity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[10] Extracellular vesicles and pasteurized cells derived from Akkermansia muciniphila protect against high-fat induced obesity in mice.

Shows: Live/pasteurized MucT and vesicles reduced HFD obesity/metabolic measures, with stronger selected effects for pasteurized cells and vesicles.

Does not show: Food intake and broad microbiota changes are alternative mediators; vesicle/preventive mouse effects cannot establish human clinical control or factor necessity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[11] Identification and Characterization of a Novel Species of Genus Akkermansia with Metabolic Health Effects in a Diet-Induced Obesity Mouse Model.

Shows: A novel Akkermansia species improved mouse weight/fat/insulin measures, with live form more effective than pasteurized.

Does not show: Different species and opposite formulation preference limit universal pasteurization superiority; no direct human MucT endpoint.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[12] Probiotic attributes and safety profile of AKM Lab-01: a novel Akkermansia muciniphila strain combating obesity and metabolic disorders in diet-induced obese mice.

Shows: AKM Lab-01 live/processed preparations improved diet-induced mouse obesity/metabolic measures and had a mouse dietary safety study.

Does not show: Calculated human safety extrapolation is not a human clinical trial or evidence of all-product long-term safety/equivalence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[13] Efficacy of multi-strain probiotic along with dietary and lifestyle modifications on polycystic ovary syndrome: a randomised, double-blind placebo-controlled study.

Shows: A six-month multi-strain plus fructooligosaccharide PCOS trial improved menstrual regularity, selected androgen/waist and quality-of-life outcomes with matched lifestyle advice.

Does not show: Mixture-specific benefits do not establish MucT or every marketed probiotic; not all listed metabolic endpoints were positive.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[14] Probiotic reduces bacterial translocation in type 2 diabetes mellitus: A randomised controlled study.

Shows: Lactobacillus casei Shirota fermented milk reduced measured bacterial translocation and changed fecal communities in 70 diabetic adults over 16 weeks.

Does not show: No-probiotic control and translocation endpoint do not establish MucT clinical glycemic benefit; blood microbial assays require contamination care.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[15] Bifidobacterium animalis subsp. lactis TISTR 2591 Improves Glycemic Control and Immune Response in Adults with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Crossover Clinical Trial.

Shows: Six-week Bifidobacterium TISTR 2591 crossover attenuated a fasting-glucose rise and changed selected insulin/lipid measures, with no body-composition change.

Does not show: Different strain, short duration and modest comparator deterioration cannot establish the 12-week MucT clinical claim or generic-product efficacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

[16] Multi-strain probiotic reduces gastrointestinal side effects in women with elevated HOMA-IR index treated with metformin: a 12-week randomised controlled trial.

Shows: Twelve-week multi-strain supplementation alleviated metformin GI symptoms but did not add metabolic/anthropometric benefit in 30 insulin-resistant women.

Does not show: Metformin-associated within-group improvements are not probiotic treatment effects; symptom benefit does not establish MucT clinical metabolism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

[17] Three probiotic strains exert different effects on plasma bile acid profiles in healthy obese adults: randomised, double-blind placebo-controlled crossover study.

Shows: Different probiotic strains altered selected plasma bile acids but not glucose, insulin or serum lipids in a placebo crossover study.

Does not show: Biochemical target movement is not clinical efficacy and the strains are not MucT; washout/period and subset context remain relevant.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[18] Lactobacillus plantarum HAC01 Supplementation Improves Glycemic Control in Prediabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial.

Shows: Eight-week HAC01 trial in 40 prediabetic adults improved two-hour glucose/HbA1c versus placebo while several insulin/microbiota endpoints remained null.

Does not show: A genuine different-strain clinical effect does not validate MucT or an unnamed commercial formula; duration is below its registered gate.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

[19] Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept.

Shows: Four-week L.reuteri in 21 glucose-tolerant adults increased incretin/insulin secretion without altering clamp insulin sensitivity, mass or ectopic fat.

Does not show: Target engagement does not establish improved phenotype or MucT-specific mechanism; short and distinct exposure cannot support universal probiotics.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[20] Probiotics to adolescents with obesity: effects on inflammation and metabolic syndrome.

Shows: Twelve-week L.salivarius Ls33 trial in 50 obese adolescents found no metabolic, inflammatory or anthropometric improvement versus placebo.

Does not show: A product/context-specific null is a generalization boundary, not a refutation of MucT or every probiotic strain.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

[21] No effect of multi-strain probiotic supplementation on metabolic and inflammatory markers and newborn body composition in pregnant women with obesity: Results from a randomized, double-blind placebo-controlled study.

Shows: Multi-strain pregnancy trial found no metabolic/inflammatory or newborn-composition benefit despite high completion.

Does not show: Pregnancy, mixture and developmental endpoints differ from MucT adult treatment; nulls cannot be erased by target presence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

[22] The Roles of Probiotics in the Gut Microbiota Composition and Metabolic Outcomes in Asymptomatic Post-Gestational Diabetes Women: A Randomized Controlled Trial.

Shows: Twelve-week six-strain post-GDM trial reported modest fasting-glucose and HbA1c/lipid differences with microbiota shifts.

Does not show: Mixture-specific biochemical/clinical glycemia effects cannot establish MucT identity or necessary microbiota mediation; long-term prevention was not demonstrated.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

[23] Is there a value for probiotic supplements in gestational diabetes mellitus? A randomized clinical trial.

Shows: Eight-week four-strain GDM trial found greater fasting-glucose decline and late weight-gain differences, but adjusted sensitivity comparison was null.

Does not show: Pregnancy-specific exposure and short horizon do not establish MucT or generic probiotics; within- versus between-group endpoints must remain separate.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

[24] Beneficial effects of a new probiotic formulation on adipocytokines, appetite-regulating hormones, and metabolic parameters in obese women.

Shows: Two strains plus octacosanol altered CRP/ghrelin in obese women over 12 weeks but did not change BMI between groups.

Does not show: Bundled active ingredient and marker-only changes cannot establish bacterial necessity, MucT clinical benefit or all-product efficacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[25] Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes.

Shows: Eight-week multispecies trial reported attenuated fasting-glucose/HOMA rise and selected inflammatory/antioxidant changes.

Does not show: Parent record has expression of concern PMID37334997; this flagged short mixture study is not used as decisive support or generalized to MucT.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ExpressionOfConcernIn: PMID37334997. Subclaims: SC2, SC4.

[26] Supplementation with Bifidobacterium breve BR03 and B632 strains improved insulin sensitivity in children and adolescents with obesity in a cross-over, randomized double-blind placebo-controlled trial.

Shows: B.breve crossover in obese youths found carryover requiring first-period analysis, with selected insulin-sensitivity changes but no cytokine/GLP1 shift.

Does not show: Carryover and interval uncertainty constrain inference; childhood, strains and marker outcomes cannot establish MucT or universal efficacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[27] The Prebiotic Effects of Oats on Blood Lipids, Gut Microbiota, and Short-Chain Fatty Acids in Mildly Hypercholesterolemic Subjects Compared With Rice: A Randomized, Controlled Trial.

Shows: Oats versus rice in 210 adults reduced selected cholesterol fractions and increased Akkermansia/Roseburia abundance over 45 days.

Does not show: Dietary components and correlated taxa do not isolate Akkermansia necessity or supplement-specific efficacy; both groups improved some lipids.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[28] Multifunctional dietary approach reduces intestinal inflammation in relation with changes in gut microbiota composition in subjects at cardiometabolic risk: the SINFONI project.

Shows: A 30-person multifunctional cereal crossover reduced local inflammation/endotoxemia and shifted microbiota, with unchanged cardiometabolic markers.

Does not show: Multi-ingredient diet and marker movement cannot demonstrate a named probiotic clinical effect or bacterial mediation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[29] A High Protein Calorie Restriction Diet Alters the Gut Microbiome in Obesity.

Shows: High/normal-protein calorie restriction in 80 obese adults altered microbiota; both diets enriched Akkermansia and Bifidobacterium.

Does not show: Diet-induced microbial abundance may accompany treatment response rather than cause it; no MucT product or necessity contrast.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[30] Timing matters in type 2 diabetes: Early high-Fiber nutrition enhances glycemic control and reshapes gut microbiota.

Shows: A 34-person crossover of early high-fiber/energy-restricted nutrition improved clinical glycemia and shifted several taxa including Akkermansia.

Does not show: Bundled energy restriction and sequence persistence preclude isolated fiber or taxon mediation; relative HbA1c-change percentages are not absolute percentage-point reductions.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

[31] The Effects of a Prebiotic Formula Promoting Akkermansia muciniphila (AKK) on Gut Health: A Single-Centre, Randomised Controlled Trial.

Shows: Eight-week prebiotic blend increased relative Akkermansia abundance in a per-protocol subset, with a trend in GI comfort.

Does not show: Seventy randomized but fifty per-protocol; abundance increase and trend do not establish clinical metabolic benefit or MucT supplement efficacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[32] Consumption of Solnul™ Resistant Potato Starch Produces a Prebiotic Effect in a Randomized, Placebo-Controlled Clinical Trial.

Shows: Four-week resistant potato starch improved bowel-pattern measures and increased relative Bifidobacterium/Akkermansia versus placebo.

Does not show: Short prebiotic laxation/abundance effects are distinct from MucT clinical metabolism and do not isolate one taxon's necessity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[33] Associations of Dietary Intake with the Intestinal Microbiota and Short-Chain Fatty Acids Among Young Adults with Type 1 Diabetes and Overweight or Obesity.

Shows: Dietary analyses within a weight-loss trial associated fiber with fecal acetate and fructose inversely with Akkermansia in young adults with T1D.

Does not show: Nonrandomized diet/taxon associations and limited repeated sampling do not establish MucT efficacy or a universal fiber-to-Akkermansia pathway.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[34] Efficacy of inulin supplementation in metabolic control and Akkermansia muciniphila levels in subjects with type 1 diabetes: a pilot study.

Shows: Three-month inulin plus insulin in 49 T1D adults modestly reduced weight/insulin need but did not improve HbA1c/CGM or Akkermansia levels versus insulin alone.

Does not show: A fiber clinical change can occur without increased Akkermansia; different diabetes and product context cannot establish pasteurized MucT efficacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

[35] Fecal Akkermansia muciniphila Is Associated with Body Composition and Microbiota Diversity in Overweight and Obese Women with Breast Cancer Participating in a Presurgical Weight Loss Trial.

Shows: Pooled secondary breast-cancer weight-loss trial analysis associated baseline Akkermansia with adiposity and fiber change in low-abundance participants.

Does not show: Randomized diet does not randomize bacterial abundance; small disease-selected associations cannot prove taxon mediation or named-product clinical efficacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[36] Distinct effects of supplementation with resistant starch and polydextrose on plasma and faecal bile acid profile and associations with gut microbiota: a randomised, controlled intervention in healthy participants.

Shows: Resistant starch and polydextrose had distinct bile-acid effects, with fiber-specific Akkermansia correlations in the DISC trial.

Does not show: Biochemical correlations are not necessary microbial mediation or clinical metabolic health; formulations cannot be grouped as uniform fiber effects.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[37] Acute and chronic improvement in postprandial glucose metabolism by a diet resembling the traditional Mediterranean dietary pattern: Can SCFAs play a role?

Shows: An isoenergetic Mediterranean-diet trial improved postprandial glucose responses with SCFA and Akkermansia shifts over eight weeks.

Does not show: Whole-diet composition and short horizon cannot identify Akkermansia-specific causal contribution or validate a MucT product.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

[38] Alterations in gut microbiota composition and metabolic parameters after dietary intervention with barley beta glucans in patients with high risk for metabolic syndrome development.

Shows: Four-week barley beta-glucan bread changed cholesterol/SCFA measures; baseline taxa differed in cholesterol responders.

Does not show: Within-group cholesterol change and post-outcome responder classification cannot establish between-group clinical microbial causality or define an unfalsifiable subgroup.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[39] Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity.

Shows: Live Akkermansia reversed HFD metabolic abnormalities in mice, whereas the tested heat-killed preparation did not; prebiotic normalization correlated with improved measures.

Does not show: Heat-killed and later pasteurized preparation protocols are not identical; experimental sufficiency does not prove endogenous human necessity or universal live superiority.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[40] Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut.

Shows: Twelve-week live AKK-WST01 trial in 58 overweight/obese T2D adults had no whole-group HbA1c or weight advantage; low-baseline exploratory participants showed selected benefit and colonization.

Does not show: Different live strain and subgroup contrasts cannot establish broad pasteurized MucT efficacy; within-subgroup significance is not automatically an interaction or independent replicated subgroup.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[41] Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice.

Shows: Purified P9 increased GLP1/thermogenesis in mice and cells; IL6 deficiency abolished selected glucose-homeostasis effects and altered its receptor pathway.

Does not show: Factor sufficiency and a knockout narrow an experimental mechanism, but do not establish that P9 mediates human pasteurized MucT clinical outcomes.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[42] Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology.

Shows: In a 49-person calorie-restriction/stabilization cohort, higher baseline Akkermansia associated with healthier status and better metabolic response while abundance subsequently declined.

Does not show: Diet and bacterial abundance are not independently randomized; a decrease alongside improvement limits a simple more-is-better abundance interpretation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[43] Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation.

Shows: Twelve-week WBF-011 mixture trial in 76 T2D adults improved postprandial glucose primary outcome and reported lower HbA1c relative to placebo.

Does not show: The five-strain/inulin product is genuinely trialed but cannot identify Akkermansia component necessity or validate MucT, another formula or every probiotic.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

[44] Akkermansia muciniphila administration ameliorates streptozotocin-induced hyperglycemia and muscle atrophy by promoting IGF2 secretion from mouse intestine.

Shows: Heat-killed Akkermansia improved STZ-mouse metabolic/muscle signaling, with intestinal IGF2 secretion and downstream muscle effects.

Does not show: Survival-selected STZ context and experimental heat-killed treatment are not a pasteurized MucT human functional trial or mediator necessity demonstration.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[45] Akkermansia muciniphila alleviates metabolic disorders through gut microbiota-mediated tryptophan regulation.

Shows: Akkermansia improved HFD zebrafish weight/survival and barrier measures; antibiotic pretreatment partly abolished selected effects with tryptophan/AhR changes.

Does not show: Broad antibiotics and metabolite associations do not isolate the exact human product or necessary human mediator; species and diet context remain explicit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[46] Akkermansia muciniphila-derived L-norleucine modulates FABP1-dependent fatty acid transport.

Shows: Intestinal FABP1 knockout and microbiota depletion narrowed lipid-absorption biology; Akkermansia supplementation and L-norleucine inhibited selected obesity/fatty-acid outcomes.

Does not show: A bacterial abundance/metabolite link and factor sufficiency do not establish human pasteurized MucT glycemic efficacy or endogenous bacterial necessity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[47] Akkermansia muciniphila in patients with metabolic dysfunction-associated steatotic liver disease.

Shows: MASLD cohort of 122 associated Akkermansia with GGT, HDL and glycemia but not ALT or AST.

Does not show: Clinical/taxon correlations and speculative oxidative-stress interpretation cannot establish product efficacy or microbial mediation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[48] Akkermansia muciniphila modulates intestinal mucus composition to counteract high-fat diet-induced obesity in mice.

Shows: Six-week live MucT in HFD mice reduced adiposity and changed mucus glycans/barrier markers without changing overall microbiota or mucus thickness.

Does not show: Living mouse supplement effects do not establish pasteurized human clinical efficacy; a mucus-composition association is not necessary mediator ablation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[49] Aberrant intestinal microbiota in individuals with prediabetes.

Shows: Prediabetes case-control microbiota had lower Akkermansia; fecal transfers from prediabetic/drug-naive diabetic donors did not impair recipient glucose regulation.

Does not show: A whole-community transfer null does not refute all Akkermansia product effects, but association cannot be counted as transferable glucose disease.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3, SC4.

[50] Comparing the effects of yogurt containing Akkermansia muciniphilia postbiotic with yogurt containing Lactobacillus rhamnosus postbiotic on body composition, biochemical indices, appetite, and depression scores in overweight or obese adults: A randomized, double-blind, controlled clinical trial.

Shows: Eight-week Akkermansia-postbiotic yogurt in 66 randomized adults improved selected waist, fat, AST and appetite outcomes versus low-fat yogurt; L.rhamnosus yogurt did not.

Does not show: Different formulation/strain details, multiple endpoints and short horizon cannot validate MucT's registered clinical glycemic/function claim; genuine context positives are retained.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

[51] Akkermansia muciniphila-derived hypoacylated rough-type lipopolysaccharides alleviate diet-induced obesity via activation of TLR4-IL-23-IL-22 immune axis.

Shows: Akkermansia-derived LPS improved obese-mouse measures; IL22 neutralization eliminated selected antiobesity effects with TLR4/IL23 pathway evidence.

Does not show: Intraperitoneal purified LPS and acute mouse toxicity comparison are not oral MucT human efficacy or universal bacterial-LPS safety.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[52] Akkermansia muciniphila and its outer membrane protein Amuc_1100 prevent high-fat diet-induced nonalcoholic fatty liver disease in mice.

Shows: Akkermansia/Amuc_1100 reduced HFD mouse weight/liver injury and metabolic measures with atorvastatin as a positive comparator.

Does not show: Broad gut/liver changes and factor administration do not establish human clinical glycemic/function effects or a unique necessary pathway.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[53] Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions.

Shows: Akkermansia vesicles improved HFD mouse weight/glucose tolerance and cell barrier function; E.coli vesicles did not reproduce selected barrier effects.

Does not show: Vesicle sufficiency and experimental positive/negative control do not establish intact pasteurized MucT clinical efficacy or vesicle necessity in humans.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[54] Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis.

Shows: Akkermansia and L-aspartate improved HFC-mouse fatty-liver measures, with persistent effects after withdrawal and partial antibiotic attenuation.

Does not show: Broad antibiotic, metabolite and liver-pathology contrasts do not isolate the human product or convert a model-specific liver result to clinical glycemic control.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[55] Akkermansia muciniphila-derived acetate activates the hepatic AMPK/SIRT1/PGC-1α axis to alleviate ferroptosis in metabolic-associated fatty liver disease.

Shows: Mouse/germ-free studies and AMPK deficiency support an Akkermansia-acetate pathway reducing selected hepatic ferroptotic injury measures.

Does not show: AMPK dependence and colonization narrow animal factor biology; no human clinical MucT endpoint or mediator necessity is established.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[56] From correlation to causality: the case of Subdoligranulum.

Shows: Subdoligranulum abundance associated with healthier human metabolic measures, but its cultured-strain supplementation did not improve eight-week obese/diabetic mouse outcomes.

Does not show: A clear association-to-intervention boundary for another taxon cannot establish MucT inefficacy; it warns against generic abundance/product inference.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[57] BATF3 Protects Against Metabolic Syndrome and Maintains Intestinal Epithelial Homeostasis.

Shows: Batf3 deficiency altered barrier/immune/microbiota state and metabolic syndrome; antibiotic and glycolysis interventions changed selected outcomes.

Does not show: Developmental host-gene perturbation and broad antibiotics cannot attribute syndrome specifically to Akkermansia or demonstrate human product efficacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[58] Mucin-dependent transcriptional dynamics of Akkermansia muciniphila in co-culture with human colonic organoids.

Shows: Human colonic organoid co-culture with goblet-cell-deficient controls showed mucin-dependent Akkermansia transcription and host-interaction genes.

Does not show: A model-specific microbial transcription response is not clinical metabolism or proof of pasteurized human-product mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[59] Binding of Akkermansia muciniphila to mucin is O-glycan specific.

Shows: Cell-based mucin arrays identify O-glycan-specific Akkermansia binding retained after pasteurization, with neuraminidase revealing binding epitopes.

Does not show: Adhesion survives processing but colonization/function and clinical glycemic benefit are not thereby established.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• ADVERSARIAL_REVIEW.akkermansia-metabolic-health.md
• CONSENSUS_CROSSCHECK.html
• CONSENSUS_CROSSCHECK.md
• RESEARCH_TIMELINE.html
• RESEARCH_TIMELINE.md
• SHA256.txt
• adversarial-findings.akkermansia-metabolic-health.json
• akkermansia-metabolic-health.review.md
• akkermansia-metabolic-health.scorecard.json
• codex-correction-provenance.json
• consensus-validation.json
• edition-approval-audit.json
• reader-summary.json
• research-timeline.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt
• video-insert.md
• web-page.md

Sources: 59 · load-bearing claims: 65 · verified: 65 · unverified: 0 · contradicted: 0 · schema 5.3